Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor-Reference-Cited by-同舟云学术

Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor

Published:2016-11-29 Issue:23 Volume:59 Page:10586-10600
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ebiike Hirosato¹,Taka Naoki²,Matsushita Masayuki¹,Ohmori Masayuki¹,Takami Kyoko²,Hyohdoh Ikumi¹,Kohchi Masami¹,Hayase Tadakatsu¹,Nishii Hiroki¹,Morikami Kenji²,Nakanishi Yoshito¹,Akiyama Nukinori¹,Shindoh Hidetoshi¹,Ishii Nobuya¹,Isobe Takehito²,Matsuoka Hiroharu²

Affiliation:

1. Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan

2. Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b01156

Reference31 articles.

1. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

2. Present Status and Problems on Molecular Targeted Therapy of Cancer